|

Tuvusertib Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: ATR Kinase Inhibitor M1774, M 1774, M-1774, M1774

Other1 trial

Tuvusertib in Astrocytoma With ATRX Mutation
Phase 2

Irvine, California1 trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1/2

Augusta, Georgia1 trial

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Augusta University Medical Center

Phase 1

Bethesda, Maryland1 trial

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

National Cancer Institute Developmental Therapeutics Clinic

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.